Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Seroconversion Rates After the...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis

Bibliographic Details
Main Authors: Nora Liebers, Stefan O. Schönland, Claudius Speer, Dominic Edelmann, Paul Schnitzler, Hans-Georg Kräusslich, Carsten Mueller-Tidow, Ute Hegenbart, Sascha Dietrich
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000688
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/HS9.0000000000000688

Similar Items

  • Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.
    by: Natalie Berghaus, et al.
    Published: (2022-01-01)
  • Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy
    by: Ute Hegenbart, et al.
    Published: (2021-12-01)
  • Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation
    by: Caroline Pabst, et al.
    Published: (2022-02-01)
  • First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
    by: Felix Korell, et al.
    Published: (2023-10-01)
  • Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report
    by: Simone Feurstein, et al.
    Published: (2022-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs